KRAS G12C clinical trials at UCSF

1 research study open to eligible people

A KRAS G12C mutation is an alteration in a cancer-related gene. UCSF is conducting tests with a drug named FMC-376 on patients with this gene change. The purpose is to evaluate the drug's effects on advanced solid tumors.

Showing trials for

  • FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

    San Francisco, California and other locations

Last updated: